How FDA Can Better Align Its Draft Guidance on Flavored ENDS with the Tobacco Control Act’s APPH Mandate

Why It Matters

Aligning the guidance with the statutory APPH mandate will shape how flavored ENDS gain market authorization, affecting both industry strategy and public‑health outcomes.

Key Takeaways

• FDA draft guidance lacks statutory alignment on comparative efficacy.
• Section 910 mandates APPH, not universal flavor comparator.
• Combustible cigarettes are proper public‑health benchmark.
• Youth vaping rates have sharply declined since 2020.
• Case‑by‑case analysis improves regulatory clarity.

Pulse Analysis

The FDA’s new draft guidance on flavored ENDS attempts to codify the evidentiary standards that applicants must meet for pre‑market approval. While the agency’s effort to provide clarity is welcomed, the guidance currently treats comparative‑efficacy evidence as a universal prerequisite, a stance that conflicts with Section 910 of the Tobacco Control Act. That statute obliges the FDA to make an overall public‑health determination—balancing adult smoking cessation benefits against youth initiation risks—rather than imposing a categorical comparator requirement.

A central contention is the choice of comparator. The draft guidance assumes tobacco‑flavored ENDS as the baseline, yet ENDS products are engineered liquids without an inherent tobacco flavor. Consequently, using a tobacco‑flavored ENDS product as the reference point can obscure the true public‑health impact. Combustible cigarettes, which remain the primary source of tobacco‑related harm, provide a more meaningful benchmark for assessing whether a flavored ENDS product can meaningfully shift adult smokers away from the most dangerous form of tobacco use.

Adopting a case‑by‑case approach that reserves comparative‑efficacy analysis for situations where the evidence warrants it will give regulators flexibility while preserving statutory fidelity. This shift matters for manufacturers seeking market entry, as it clarifies the evidentiary pathway and reduces uncertainty. Moreover, with youth vaping rates now markedly lower than during the pandemic surge, a nuanced, evidence‑driven framework aligns regulatory oversight with current public‑health realities, supporting adult harm reduction without imposing unnecessary barriers.